Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis

Abstract

Background:

Multiple sclerosis (MS) is a chronic, progressive, and disabling disease of the central nervous system with dramatic variations in the combination and severity of symptoms it can produce. The lack of reliable disease-specific health-related quality of life (HRQL) measures for use in clinical trials prompted the development of the Neurology Quality of Life (Neuro-QOL) instrument, which includes 13 scales that assess physical, emotional, cognitive, and social domains, for use in a variety of neurological illnesses.

Objective:

The objective of this research paper is to conduct an initial assessment of the reliability and validation of the Neuro-QOL short forms (SFs) in MS.

Methods:

We assessed reliability, concurrent validity, known groups validity, and responsiveness between cross-sectional and longitudinal data in 161 recruited MS patients.

Results:

Internal consistency was high for all measures (α = 0.81–0.95) and ICCs were within the acceptable range (0.76–0.91); concurrent and known groups validity were highest with the Global HRQL question. Longitudinal assessment was limited by the lack of disease progression in the group.

Conclusions:

The Neuro-QOL SFs demonstrate good internal consistency, test-re-test reliability, and concurrent and known groups validity in this MS population, supporting the validity of Neuro-QOL in adults with MS.

Keywords

Neuro-QOL multiple sclerosis health-related quality of life patient-reported outcomes

Get full access to this article

View all access options for this article.

References

Noseworthy

Lucchinetti

Rodriguez

. Multiple sclerosis. N Engl J Med 2000; 343: 938–952.

National Institute of Neurological Disorders and Stroke (NINDS). Multiple sclerosis: Hope through research, http://www.ninds.nih.gov/disorders/multiple_sclerosis/detail_multiple_sclerosis.htm (accessed 27 February 2012).

Rudick

Miller

Clough

. Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 1992; 49: 1237–1242.

Chopra

Herrman

Kennedy

. Comparison of disability and quality of life measures in patients with long-term psychotic disorders and patients with multiple sclerosis: An application of the WHO Disability Assessment Schedule II and WHO Quality of Life-BREF. Int J Rehabil Res 2008; 31: 141–149.

Miller

Kattan

. Health-related quality of life assessment in multiple sclerosis. In: Cohen

Rudick

(eds) Multiple sclerosis theraputics. 4th ed. New York: Cambridge University Press, 2011, pp.79–90.

Cella

Nowinski

Peterman

. The Neurology Quality-of-Life Measurement (Neuro-QOL) initiative. Arch Phys Med Rehabil 2011; 92 (10 Suppl): S28–S36.

Cella

Victorson

Nowinski

. The Neuro-QOL project: Using multiple methods to develop a HRQOL measurement platform to be used in clinical research across neurological conditions. Qual Life Res 2006; A14: 1353.

Miller

Nowinski

Victorson

. The Neuro-QOL project: Establishing research priorities through qualitative research and consensus development. Qual Life Res 2005; 14: 2031.

Perez

Huang

Jansky

. Using focus groups to inform the Neuro-QOL measurement tool: Exploring patient-centered, health-related quality of life concepts across neurological conditions. J Neurosci Nurs 2007; 39: 342–353.

10.

Cella

Lai

Nowinski

. Neuro-QOL: Brief measures of health-related quality of life for clinical research in neurology. Neurology 2012; 78: 1860–1867.

11.

Gershon

Lai

Bode

. Neuro-QOL: Quality of life item banks for adults with neurological disorders: Item development and calibrations based upon clinical and general population testing. Qual Life Res 2012; 21: 475–486.

12.

National Institute of Neurological Disorders and Stroke (NINDS). User manual for the Quality of Life in Neurological Disorders (Neuro-QOL) measures, version 1.0, http://www.neuroqol.org/Instruments%20%20Tools/Neuro-QOL_UserManual.pdf (September 2010, accessed 15 December 2014).

13.

Karnofsky

Burchenal

. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod

(ed.) Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949, pp.199–205.

14.

Smith

. Symbol Digit Modalities Test. Los Angeles, CA: Psychological Services, 1991.

15.

Rabin

de Charro

. EQ-5D: A measure of health status from the EuroQol Group. Ann Med 2001; 33: 337–343.

16.

Johnson

Coons

Ergo

. Valuation of EuroQOL (EQ-5D) health states in an adult US sample. Pharmacoeconomics 1998; 13: 421–433.

17.

Hays

Bjorner

Revicki

. Development of physical and mental health summary scores from the Patient-Reported Outcomes Measurement Information System (PROMIS) global items. Qual Life Res 2009; 18: 873–880.

18.

Cella

. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT Scales). Evanston, IL: Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University, 1997.

19.

Jaeschke

Singer

Guyatt

. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407–415.

20.

Yost

Eton

Garcia

. Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol 2011; 64: 507–516.

21.

Rudick

Cutter

Baier

. Use of the Multiple Sclerosis Functional Composite in predicting disability in relapsing MS. Neurology 2001; 56: 1324–1330.

22.

Cella

Dineen

Arnason

. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996; 47: 129–139.

23.

Benedict

Wahlig

Bakshi

. Predicting quality of life in multiple sclerosis: Accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci 2005; 231: 29–34.

24.

Langdon

. Cognition in multiple sclerosis. Curr Opin Neurol 2011; 24: 244–249.

25.

Bruce

Hancock

. Self-reported memory problems in multiple sclerosis: Influence of psychiatric status and normative dissociative experiences. Arch Clin Neuropsychol 2010; 25: 39–48.

26.

Cella

Choi

Garcia

. Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment. Qual Life Res 2014; 23: 2651–2661.

27.

Cook

Victorson

Cella

. Creating meaningful cut-scores for Neuro-QOL measures of fatigue, physical functioning, and sleep disturbance using standard setting with patients and providers. Qual Life Res 2015; 24: 575–589.